Getinge AB (GNGBY)
OTHER OTC:GNGBY
GNGBY Stock Chart & Stats
$22.97
$0.02(0.10%)
At close: 4:00 PM EST
$22.97
$0.02(0.10%)
Day’s Range― - ―
52-Week Range$17.80 - $24.82
Previous CloseN/A
Volume7.12K
Average Volume (3M)149.00
Market Cap
$5.49B
Enterprise Value$59.56B
Total Cash (Recent Filing)$3.40B
Total Debt (Recent Filing)$10.88B
Price to Earnings (P/E)26.3
Beta0.64
Next Earnings
Apr 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.05%
Share Statistics
EPS (TTM)0.34
Shares Outstanding254,152,370
10 Day Avg. Volume133
30 Day Avg. Volume149
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)2.02
Price to Sales (P/S)1.70
P/FCF Ratio23.97
Enterprise Value/Market Cap10.85
Enterprise Value/Revenue1.71
Enterprise Value/Gross Profit3.74
Enterprise Value/Ebitda9.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Manageable LeverageGetinge's balance sheet shows moderate leverage (debt-to-equity ~0.27–0.37) and net debt metrics that management reports as manageable. This financial flexibility supports continued R&D, product launches, dividend payments and withstands cyclical shocks, reducing refinancing and solvency risk over the medium term.
High And Growing Recurring Revenue MixRecurring revenue comprising roughly two-thirds of sales increases revenue predictability and margin durability from consumables, services and installed-base monetization. A higher recurring share buffers capital spend cyclicality, supports steadier cash generation and underpins medium-term margin recovery.
Product Launches And Regulatory ProgressConcrete regulatory milestones and launches (CardioSave 510(k) timing, Cardiohelp II CE submission, multiple device rollouts) expand Getinge's addressable market and cross-sell opportunities. These durable improvements in product portfolio and approvals support organic growth and structural margin improvement when fully commercialized.
Bears Say
Material Tariff And FX HeadwindsPersistent tariffs (~SEK 370m in 2025) and FX effects that together trimmed over SEK 1bn of adjusted EBITDA are structural near-term headwinds. These external cost pressures compress reported margins, limit operating leverage benefits and force price/productivity actions that can take quarters to fully offset.
Volatile And Downshifted Free Cash FlowAlthough FCF remains positive, a ~20% decline in 2025 and historical volatility reduce cushion for capex, M&A or rapid deleveraging. Lower and variable cash conversion increases sensitivity to operational hiccups and makes multi-year investment planning and dividend consistency more challenging without offsetting margin improvements.
Elevated Quality Remediation And Execution RiskSustained extraordinary quality costs (substantial in 2025) signal execution and compliance issues that erode margins and delay product commercialization. These remediation expenses can persist through H2 2026, raise warranty/service costs, and slow realization of efficiency gains from new product launches.
Getinge AB News
GNGBY FAQ
What was Getinge AB’s price range in the past 12 months?
Getinge AB lowest stock price was $17.80 and its highest was $24.82 in the past 12 months.
What is Getinge AB’s market cap?
Getinge AB’s market cap is $5.49B.
When is Getinge AB’s upcoming earnings report date?
Getinge AB’s upcoming earnings report date is Apr 21, 2026 which is in 14 days.
How were Getinge AB’s earnings last quarter?
Getinge AB released its earnings results on Jan 27, 2026. The company reported $0.339 earnings per share for the quarter, beating the consensus estimate of N/A by $0.339.
Is Getinge AB overvalued?
According to Wall Street analysts Getinge AB’s price is currently Overvalued.
Does Getinge AB pay dividends?
Getinge AB pays a Annually dividend of $0.478 which represents an annual dividend yield of 2.05%. See more information on Getinge AB dividends here
What is Getinge AB’s EPS estimate?
Getinge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Getinge AB have?
Getinge AB has 254,152,370 shares outstanding.
What happened to Getinge AB’s price movement after its last earnings report?
Getinge AB reported an EPS of $0.339 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.944%.
Which hedge fund is a major shareholder of Getinge AB?
Currently, no hedge funds are holding shares in GNGBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Getinge AB Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.55%
12-Months-Change
Fundamentals
Return on Equity
7.66%
Trailing 12-Months
Asset Growth
2.81%
Trailing 12-Months
Company Description
Getinge AB
Getinge AB is a global medical technology company based in Sweden, specializing in advanced solutions for healthcare professionals in the hospital and life sciences sectors. The company operates primarily in three areas: Surgical Workflows, Critical Care, and Life Science. Getinge's core products include surgical instruments, sterilization systems, intensive care unit equipment, and biopharmaceutical manufacturing solutions, aimed at improving patient outcomes and enhancing operational efficiency in healthcare facilities.
GNGBY Company Deck
GNGBY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: underlying operational performance, recurring revenue mix, product launches, regulatory progress and a strong balance sheet are clear positives. However, significant external headwinds — notably tariffs and currency moves — materially suppressed reported margins and profitability in 2025 and are expected to persist into 2026. Additionally, softness in parts of Life Science, supply delays for CardioSave and elevated quality‑related costs temper near‑term visibility. Management is confident in mitigation actions and progression toward the mid‑term margin target, but the combination of solid fundamentals and notable external pressures results in a balanced outlook.View all GNGBY earnings summariesTechnical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---